Ying Dou

Ying Dou

Auto-generated profile, based on publicly available information

Ying Dou

School of Biomedical Sciences, The University of Hong Kong, Hong Kong, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2020 in Bioengineering & Translational Medicine
Verified
Journal Article
Open access
PDF file
CKChaiyaporn Kuwentrai
Chaiyaporn Kuwentrai
JYJinming Yu
Jinming Yu
LRLi Rong
Li Rong
BZBao-zhong Zhang
Bao-zhong Zhang
YHYe-Fan Hu
Ye-Fan Hu
Chenjie XuChenjie Xu
Chenjie Xu
The S1 subunit of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) spike protein contains an immunogenic receptor‐binding domain (RBD), which is a promising candidate for the development of a potential vaccine. This study demonstrated that intradermal delivery of an S‐RBD vaccine using a dissolvable microneedle skin patch can induce both significant B‐cell and significant T‐cell responses against S‐RBD. Importantly, the outcomes were comparable to that of conventional bolus injection.

1 August 2021 in EBioMedicine
Verified
Journal Article
Open access
JDJian Deng
Jian Deng
BZBao-zhong Zhang
Bao-zhong Zhang
HIN CHUHIN CHU
HIN CHU
XWXiao-Lei Wang
Xiao-Lei Wang
Yi-Xin WangYi-Xin Wang
Yi-Xin Wang
JHJian-Dong Huang
Jian-Dong Huang
Background: Staphylococcus aureus is a common human pathogen capable of causing diverse illnesses with possible recurrent infections. Although recent studies have highlighted the role of cellular immunity in recurrent infections, the mechanism by which S. aureus evades host responses remains largely unexplored.

17 May 2021 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
CKChaiyaporn Kuwentrai
Chaiyaporn Kuwentrai
JYJinming Yu
Jinming Yu
BZBao-zhong Zhang
Bao-zhong Zhang
YHYe-Fan Hu
Ye-Fan Hu
YDYing Dou
Ying Dou
Chenjie XuChenjie Xu
Chenjie Xu
The nucleocapsid protein (NP) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contains immunogenic epitopes that can induce cytotoxic T lymphocyte (CTL) against viral infection. This makes the nucleocapsid protein a suitable candidate for developing a vaccine against SARS-CoV-2 infection. This article reports the intradermal delivery of NP antigen using dissolvable microneedle skin patches that could induce both significant B cell and T cell responses.